RESEARCH GROUPS

Projects

• Análisis del Coste-Efectividad del Tratamiento con Estatinas en la Prevención PRimaria de Eventos Vasculares. Proyecto EPREV

  Funding entity: (2010 - 2012)

• Association between sudden changes in ambient temperature and cardiovascular hospitalisations or mortality: a population study from Catalonia (SURIA Study).

  Funding entity: (2015 - 2018)

• Avances en el manejo del riesgo intermedio. Estudio MARK (improving interMediAte RisK management)

  Funding entity: (2010 - 2014)

• Causes and prognosis of CKD: a population-based epidemiological study

  Funding entity: (2017 - 2017)

• Characterization of the individuals with high cardiovascular risk in Catalonia regarding their cholesterol level and lipid-lowering treatment

  Funding entity: (2015 - 2017)

• Drug utilization of Intrarosa (6.5 mg prasterone pessary) in European Countries

  Principal Investigator: Rafel Ramos Blanes

  Funding entity: (2020)

Recent publications

• Seco-Meseguer E, Stewart S, Diago-Sempere E, Jiménez C, Macías Carmona N, Fernández Solís J, Vila Santandreu A, Valero San Cecilio R, López Jiménez V, Carmona-Rodríguez M, López-Fernández LA, Imaz-Iglesia I, García-Saiz MDM, Farré M, Rodriguez-Jimenez C, Sanabria-Cabrera J, Rosas-Alonso R, García-García I, Borobia AM, . Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial.. BMJ Open. 2026 Aug;16:e109279. doi:10.1136/bmjopen-2025-109279. Epub 2026 Aug 03. pmc:PMC13435983. PMID:42547238.

• Martin-Cardona A, Horta D, Florez-Diez P, Vela M, Mesonero F, Ramos Belinchón C, García MJ, Masnou H, de la Peña-Negro L, Suarez Ferrer C, Casanova MJ, Durán MO, Peña E, Calvet X, Fernández-Prada SJ, González-Muñoza C, Piqueras M, Rodríguez-Lago I, Sainz E, Bas-Cutrina F, Mancediño Marcos N, Ojeda A, Orts B, Sicilia B, García AC, Domènech E, Esteve M; ENEIDA registry of GETECCU. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease. Dig Liver Dis. 2024 Mar; 56(3):468-476. doi:10.1016/j.dld.2023.09.004. Epub 2023 Sep 26. PMID:37770282.

• Garcia-Gil M, Alves-Cabratosa L, Cunillera O, Blanch J, Martí-Lluch R, Ponjoan A, Ribas-Aulinas F, Tornabell-Noguera È, Zacarías-Pons L, Domínguez-Armengol G, Guzmán E, Ramos R. Effectiveness of the low-density lipoprotein cholesterol goals in secondary cardiovascular prevention. Eur J Clin Invest. 2024 Jun; doi:10.1111/eci.14258. Epub 2024 Jun 03. PMID:38828496.

• Ponjoan A, Blanch J, Fages-Masmiquel E, Martí-Lluch R, Alves-Cabratosa L, Garcia-Gil MDM, Domínguez-Armengol G, Ribas-Aulinas F, Zacarías-Pons L, Ramos R. Sex matters in the association between cardiovascular health and incident dementia: evidence from real world data. Alzheimers Res Ther. 2024 Mar; 16(1):58. doi:10.1186/s13195-024-01406-x. Epub 2024 Mar 14. PMID:38481343.

• Alves L, Elosua M, Martí R, Blanch J, Tornabell E, Garcia M, Ponjoan A, Grau M, Ribas F, Zacarías L, Ramos R. Cardiovascular Risk Age Reflects Arterial Status: Middle-Aged People Showed Equivalent Arterial Stiffness to Older People in the Same Risk Category. J Atheroscler Thromb. 2024;31(5):426-440. PMID:38171907.

• Ponjoan A, Jacques C, Medina L, Romero V, Martí R, Alves L, Ramos R, Garcia MD. Axes of social inequities in COVID-19 clinical trials: A systematic review. Front Public Health. 2023;11:1069357--. PMID:36891333.